Showing 8381-8390 of 9671 results for "".
- AcneCareMD Website Launcheshttps://practicaldermatology.com/news/acnecaremd-website-launches/2458957/Jamie Altman, MD, owner and president of Aesthetic Dermatology Associates, PC, in Media and Paoli, PA, launched AcneCareMD.com, a secure telemedicine website to provide acne care to patients across Pennsylvania via
- Provectus Opens Phase 3 Trial Enrollment for Investigational Melanoma Agenthttps://practicaldermatology.com/news/provectus-opens-phase-3-trial-enrollment-for-investigational-melanoma-agent/2458965/Provectus Biopharmaceuticals, Inc. has opened enrollment of patients for its phase 3 international FDA comparative clinical trial of PV-10 for melanoma. The study is an international multicenter, open-label, randomized controlled trial of single-agent intralesional PV-10 versus systemic chemother
- Foamix Pharmaceuticals Announces Upsizing and Pricing of Its Public Offeringhttps://practicaldermatology.com/news/foamix-pharmaceuticals-announces-upsizing-and-pricing-of-its-public-offering/2458968/Foamix Pharmaceuticals Ltd. (Nasdaq:FOMX), a specialty pharmaceutical company focused on developing topical foams to address unmet needs in dermatology, today announced the pricing of an upsized public offering of 6,451,612 ordinary shares at a price to the public of $9.30 per share. In addition,
- FixMySkin Unveils New Lookhttps://practicaldermatology.com/news/fixmyskin-unveils-new-look/2458974/FixMySkin Healing Balms with 1% Hydrocortisone have a new look with the same great formula. Now available in environmentally friendly packaging, these balms come in two convenient sizes for the lips and body. Th
- Promius Pharma Launches Zenatane 30mg Dosehttps://practicaldermatology.com/news/promius-pharma-launches-zenatane-30mg-dose/2458977/Promius Pharma, LLC has announced that ZENATANE™(Isotretinoin Capsules USP) are now available in a 30mg dose. Zenatane, AB rated equivalent to Accutane 30mg, has been introduced in response to dermatologists who have continued to request this strength of the drug. <
- Alma Lasers Introduces Harmony XL Pro Multi-Application Platformhttps://practicaldermatology.com/news/alma-lasers-introduces-harmony-xl-pro-multi-application-platform/2458987/Alma Lasers introduced the Harmony XL Pro™ platform to its product portfolio. The platform will be presented at the American Academy of Dermatology Meeting in San Francisco, CA from March 21 - 23 at Booth 2428. The Harmony XL Pro platform consists of multiple modules offering powerf
- Practical Dermatology® and DermTube to Offer Daily Video Coverage of AAD Annual Meetinghttps://practicaldermatology.com/news/practical-dermatology-and-dermtube-to-offer-daily-video-coverage-of-aad-annual-meeting/2458988/As the annual meeting of the American Academy of Dermatology gets underway this week, Practical Dermatology® and DermTube.com are set to bring you daily video coverage and live updates
- Novel Anti-Biofilm AQUACEL™ Ag+ Dressing Demonstrates Positive Results in Hard-to-Heal Woundshttps://practicaldermatology.com/news/novel-anti-biofilm-aquacel-ag-dressing-demonstrates-positive-results-in-hard-to-heal-wounds/2458998/A new, multi-country, clinical evaluation study showed that AQUACEL™ Ag+ wound dressing demonstrated positive results in wounds, including those compromised by biofilm and/or infection. AQUACEL™ Ag+ dressings are designed to disrupt biofilm and kill infection-
- Investigational Atopic Dermatitis Cream Disappoints in Phase II Trialhttps://practicaldermatology.com/news/investigational-atopic-dermatitis-cream-disappoints-in-phase-ii-trial/2459003/Results from a phase II trial do not bode well for the future of the investigational atopic dermatitis cream MRX-6. The double-blind, parallel-group, vehicle-controlled study evaluated the safety and efficacy of MRX-6 cream 2% among 73 children suffering from mild-to-moderate atopic dermatitis. P
- Kythera Acquires Rights to Experimental Hair Loss Treatmenthttps://practicaldermatology.com/news/kythera-acquires-rights-to-experimental-hair-loss-treatment/2459008/Kythera Biopharmaceuticals has struck two separate license agreements with Actelion Pharmaceuticals and the University of Pennsylvania for a potential novel treatment of hair loss. In the agreement with Actelion, Kythera gained licensing of the worldwide rights to setipiprant, a clinical-stage se